Cargando…

Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report

BACKGROUND: Severe hypercalcemia is often associated with uncontrolled malignancy through several mechanisms. However, calcitriol-mediated hypercalcemia is a rare etiology for advanced solid tumors. CASE PRESENTATION: We report a case of calcitriol-mediated hypercalcemia secondary to immune checkpoi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnson, Kai, Issa, Majd, Parikh, Anish, Monk, Paul, Yin, Ming, Mortazavi, Amir, Yang, Yuanquan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017871/ https://www.ncbi.nlm.nih.gov/pubmed/33794867 http://dx.doi.org/10.1186/s12894-021-00825-4

Ejemplares similares

Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
por: Gautron Moura, Bianca, et al.
Publicado: (2022)

Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis
por: Zhao, Xin, et al.
Publicado: (2022)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Salvage nivolumab and ipilimumab after prior anti‐PD‐1/PD‐L1 therapy in metastatic renal cell carcinoma: A meta‐analysis
por: Yang, Yuanquan, et al.
Publicado: (2022)

Pembrolizumab Induced Calcitriol-Mediated Hypercalcemia
por: Oommen, Tiffany T., et al.
Publicado: (2023)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
por: Zhou, Shi, et al.
Publicado: (2019)

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data
por: Soldatos, Theodoros G., et al.
Publicado: (2018)

Ipilimumab in the treatment of metastatic melanoma: management of adverse events
por: Della Vittoria Scarpati, Giuseppina, et al.
Publicado: (2014)

SAT-502 Bisphosphonates for Treatment of Calcitriol-Induced Hypercalcemia
por: Mateo, Roselyn Cristelle, et al.
Publicado: (2019)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Hypercalcemia in metastatic GIST caused by systemic elevated calcitriol: a case report and review of the literature
por: Hygum, Katrine, et al.
Publicado: (2015)

MON-LB69 Calcitriol-Mediated Hypercalcemia in a Patient With Metastatic Gastrointestinal Stromal Tumor
por: Betlachin, Anna, et al.
Publicado: (2020)

SUN-414 Immune Related Adverse Events: Isolated ACTH Deficiency with Nivolumab/Ipilimumab Combination Therapy
por: Magdaleno, Angela, et al.
Publicado: (2019)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Malignant Hypercalcemia Due to the Ectopic Production of Calcitriol by an Abdominal Liposarcoma
por: Figueiredo, Ana, et al.
Publicado: (2023)

Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report
por: Miyauchi, Yasuyuki, et al.
Publicado: (2021)

Excellent Response to Nivolumab and Ipilimumab in Metastatic Gastroesophageal Junction Squamous Carcinoma
por: Sadagopan, Narayanan, et al.
Publicado: (2019)

Ipilimumab and Nivolumab-Induced Colitis in a Patient With Recurrent Metastatic Melanoma
por: Moein, Hamid-Reza, et al.
Publicado: (2021)

Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma
por: Danno, Tetsuya, et al.
Publicado: (2021)

Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook
por: Möhn, Nora, et al.
Publicado: (2019)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
por: Apolo, Andrea B., et al.
Publicado: (2020)

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2018)

Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience
por: Karivedu, Vidhya, et al.
Publicado: (2019)

Onset of azoospermia in man treated with ipilimumab/nivolumab for BRAF negative metastatic melanoma
por: Rabinowitz, Matthew J., et al.
Publicado: (2020)

Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients
por: Stoff, Ronen, et al.
Publicado: (2022)

Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma
por: Segawa, Takuya, et al.
Publicado: (2023)

Nivolumab–ipilimumab in renal cell carcinoma metastatic to the bones: A case report
por: Di Napoli, Marilena, et al.
Publicado: (2022)

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
por: Najjar, Yana G, et al.
Publicado: (2020)

Hypercalcemia associated with dysgerminoma and elevation of calcitriol: A case report and review of the literature
por: Hara, Natsuko, et al.
Publicado: (2022)

Calcitriol-Mediated Hypercalcemia from Hepatic Granulomatosis Following Percutaneous Cholecystostomy Tube
por: Cater, Taylor, et al.
Publicado: (2021)

Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review
por: Nakamura, Hajime, et al.
Publicado: (2023)

Corrigendum to “Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience”
por: Karivedu, Vidhya, et al.
Publicado: (2019)

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
por: Yoshida, Saaya, et al.
Publicado: (2019)

Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report
por: Guercio, Brendan John, et al.
Publicado: (2021)

Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab
por: Fuchizawa, Hirotaka, et al.
Publicado: (2021)

Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
por: Savarapu, Pramod, et al.
Publicado: (2021)

Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma
por: Kraehenbuehl, Lukas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bd5d3dg2us675dhnl2ncl303uh